🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the effort against drug-resistant strains of the pathogen, according to researchers.

A Worldwide Challenge

Gonorrhoea infections are on the rise worldwide, with data suggesting in excess of 82 million infections each year. Particularly high rates are seen in Africa and countries within the World Health Organization's designated area, which includes Mongolia and China to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to those in 2014.

“The clearance of new treatments for gonorrhoea is an significant and necessary advancement in the context of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the rise in drug-resistant strains. The World Health Organization has designated it as a "high-priority threat". A tracking program found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Therapies Secure Authorization

One new antibiotic, alternatively called a brand name, was approved by the US Food and Drug Administration in mid-December for combating gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the drugmaker GSK, gained clearance in close succession. This drug, which is also used to treat UTIs, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to bring it to fruition.

“This milestone represents a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been outpacing medical innovation.”

Clinical Trial Outcomes and Global Access

According to findings published in a major medical journal, the new drug successfully treated the vast majority of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which combines two antibiotics. The study included hundreds of participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the authority to license and sell the drug in many low-income and middle-income countries.

Clinicians on the front lines have voiced positive views. The availability of a one-pill regimen such as this is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to lessen the impact of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea around the world.